Stockscreener 앱 받기
67.71
1.67%
-1.15
시장 영업 전:
67.90
0.19
+0.28%
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
Oruka Therapeutics COO Laura Sandler sells $41,814 in ORKA shares - Investing.com
Oruka Therapeutics general counsel Paul Quinlan sells $51,082 in stock - Investing.com
Oruka Therapeutics CMO Joana Goncalves sells $550,606 in stock - Investing.com
Oruka Therapeutics SVP of finance Arjun Agarwal sells $687k in stock By Investing.com - Investing.com India
Oruka Therapeutics general counsel Paul Quinlan sells $51,082 in stock By Investing.com - Investing.com India
Oruka Therapeutics (ORKA) SVP exercises options, sells shares to cover tax obligations - Stock Titan
Oruka Therapeutics (ORKA) CMO sells shares and exercises stock options - Stock Titan
Oruka Therapeutics (ORKA) CEO has 1,729 shares sold for RSU tax withholding - Stock Titan
Oruka Therapeutics (ORKA) COO sells 600 shares to cover taxes - Stock Titan
Oruka Therapeutics (ORKA) counsel sells 733 shares in tax sell-to-cover - Stock Titan
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade - MSN
Insider Sell: Carl Dambkowski Sells 35,000 Shares of Oruka Thera - GuruFocus
Certain Warrants of Oruka Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JUN-2026. - marketscreener.com
Certain Series B Preferred Stock of Oruka Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JUN-2026. - marketscreener.com
Oruka Therapeutics (ORKA) director sells 35,000 shares under Rule 10b5-1 plan - Stock Titan
Oruka Therapeutics, Inc. (ORKA) upgraded to buy: What does it mean for the stock? - MSN
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
ORKA (NASDAQ: ORKA) notice to sell 35,000 shares; insider sold 105,000 - Stock Titan
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
ORKA News | ORUKA THERAPEUTICS INC (NASDAQ:ORKA) - ChartMill
Basic earnings per share (basic EPS) of Oruka Therapeutics, Inc. – XETR:HQ1 - TradingView
Is Oruka’s Broadened IL-23 License Reshaping Optionality And Altering The Investment Case For Oruka Therapeutics (ORKA)? - simplywall.st
Gross margin % of Oruka Therapeutics, Inc. – XETR:HQ1 - TradingView
Asset turnover of Oruka Therapeutics, Inc. – XETR:HQ1 - TradingView
Oruka Therapeutics, Inc. Statistics – XETR:HQ1 - TradingView
Oruka Therapeutics, Inc. Income Statement – XETR:HQ1 - TradingView
ETFs Investing in Oruka Therapeutics, Inc. Stocks - TradingView
Halozyme licenses Hypercon technology to Oruka for psoriasis drug - Investing.com
Oruka Therapeutics Shareholders Back Governance and Executive Pay - TipRanks
Oruka Therapeutics (ORKA) investors approve directors, auditor and executive pay - Stock Titan
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy By Investing.com - Investing.com South Africa
Oruka Therapeutics (ORKA) director awarded 9,136 stock options with 2036 expiry - Stock Titan
Oruka Therapeutics (ORKA) grants director 9,136 stock options - Stock Titan
Director at Oruka Therapeutics (ORKA) receives 9,136 stock options award - Stock Titan
Oruka Therapeutics (ORKA) director granted 9,136 stock options - Stock Titan
Oruka Therapeutics (NASDAQ: ORKA) grants 9,136-share option to Fairmount-managed funds - Stock Titan
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy - Investing.com
Oruka Therapeutics stock rating reaffirmed by Piper Sandler at Overweight - Investing.com Canada
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Oruka Therapeutics Expands IL-23 License, Adds Dosing Limits - TipRanks
Oruka Therapeutics (NASDAQ: ORKA) widens IL-23 rights but delays IBD dosing - Stock Titan
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million - Yahoo Finance
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million - The Motley Fool
Number of shareholders of Oruka Therapeutics, Inc. – NASDAQ:ORKA - TradingView
Number of shareholders of Oruka Therapeutics, Inc. – SWB:HQ1 - TradingView
Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors - AOL.com
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Encouraging ORKA-001 Psoriasis Data and Upsized Offering Could Be A Game Changer For Oruka Therapeutics (ORKA) - Sahm
Oruka Therapeutics(ORKA.US) Director Sells US$6.19 Million in Common Stock - Moomoo
Wedbush Adjusts Price Target on Oruka Therapeutics to $165 From $85, Maintains Outperform Rating - Moomoo
Oruka Therapeutics director Carl Dambkowski sells $6.19m in stock - Investing.com India
Oruka Therapeutics director Carl Dambkowski sells $6.19m in stock By Investing.com - Investing.com Canada
1.27%
1.43%
자본화:
|
볼륨(24시간):